Researchers based at Pfizer’s Ophthalmology External Research Unit in San Diego, have published supporting animal data showing that a clinical stage siRNA experimental drug (PF-04523655) is capable of decreasing the incidence of clinical grade 3 or 4 choroidal neovascularization (CNV) lesions by approximately 60% (P=0.053). In addition, the researchers showed a dose dependent inhibition of the siRNA target gene (the RTP801 stress response gene)(P < 0.01). The researchers suggest that the reduced RTP801 expression is consistent with the RNA-induced silencing complex (RISC) mechanism of action and that the data may be useful to clinical study design.
Pre-clinical siRNA data shows targeting of stress response gene may have therapeutic benefit for CNV
- by swdadmin